Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Seattle Genetics to...

    Seattle Genetics to resume trials as FDA lifts clinical hold

    Written by supriya kashyap kashyap Published On 2017-03-07T10:58:44+05:30  |  Updated On 7 March 2017 10:58 AM IST
    Seattle Genetics to resume trials as FDA lifts clinical hold

    Seattle Genetics Inc said the U.S. Food and Drug Administration lifted a clinical hold on several early stage studies testing its experimental cancer drug.


    The FDA imposed the clinical hold in December after the company reported the deaths of four people in trials testing the experimental cancer drug, vadastuximab talirine.


    Seattle Genetics said the clinical hold was resolved through a comprehensive study evaluating more than 300 patients and amendments to further enhance safety.


    The company said it would resume two early-stage trials and initiate a mid-stage trial of vadastuximab talirine in 2017, in patients with acute myeloid leukemia (AML), a type of blood cancer.


    The drug would continue to be tested in an ongoing late-stage study in older AML patients, the company said.


    AML is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white-blood cell), red blood cells, or platelets.


    Vadastuximab talirine, which has an orphan drug status from both the USFDA and European regulators for the treatment of AML, is also being tested in patients with myelodysplastic syndrome, another form of blood cancer.


    Last month, Seattle Genetics entered into a development and licensing deal worth up to $2 billion with Immunomedics Inc to bolster its cancer drug pipeline.


    Up to Friday's close, Seattle Genetics' shares had risen about 15 percent since the deal with Immunomedics.

    acute myeloid leukemiaAMLblood cancerbone marrowcancer drugsSeattle GeneticsUSFDAvadastuximab talirine
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok